Patent: 7,722,857

Summary for Patent: 7,722,857

Title:	Immunoadjuvant
Abstract:	An immunoadjuvant comprising one kind or two or more kinds of immunostimulating substances carried separately by two or more kinds of different microparticle immunostimulating substance carriers, and comprising at least a combination of (a) an inorganic substance such as microparticle calcium phosphate having a size phagocytizable by cells, and (b) precipitates of a soluble protein and a mucopolysaccharide formed by coacervation as the microparticle immunostimulating substance carriers, which is highly safe and can exhibit potent immunoadjuvant activity.
Inventor(s):	Ohno; Tadao (Ibaraki, JP), Uchimura; Eiji (Chiba, JP)
Assignee:	Cell-Medicine, Inc. (Ibaraki, JP)
Application Number:	12/159,907
Patent Claims:	see list of patent claims

Patent 7,722,857 analysis: claims, critical validity issues, and US patent landscape for a calcium phosphate + coacervate immunoadjuvant

United States Patent 7,722,857 (US7722857) claims an immunoadjuvant defined by a two-carrier architecture: (i) microparticle calcium phosphate (MCP) with specific crystallinity, Ca/P, carbonate content, and particle size constraints, paired with (ii) coacervated precipitates formed from a soluble protein and a mucopolysaccharide (protein/mucopolysaccharide coacervation), where both are used as different microparticle carriers for immunostimulating substances. The claim set is broad on immunostimulant selection (cytokines, PRR ligands, microbial components, small-molecule inducers, etc.) but narrow on the physicochemical carrier specifications, especially crystallinity criteria in XRD and Ca/P/carbonate limits for the MCP, and albumin/heparin/coacervate crosslinking options in dependent claims.

Top-line patentability and freedom-to-operate (FTO) implication: the most infringement-relevant elements are the MCP XRD crystallinity window (including peak/shoulder centers at specified 2θ values with Miller indices), Ca/P ≥ 1.3, carbonate groups 1–15 wt%, and the coacervate precipitate formed by protein + mucopolysaccharide. Many “calcium phosphate adjuvant” and “protein–polysaccharide coacervate” teachings exist separately, but fewer references combine both as defined and then bind the MCP to those specific XRD/carbonate/Ca/P parameters. Validity risk for US7722857 typically concentrates on whether prior art already disclosed (a) carbonate-containing calcium phosphate microparticles with that crystallinity window and (b) coacervate protein/polysaccharide adjuvant precipitates used in a combined carrier system for immunostimulation.

---

What patents protect US 7,722,857 immunoadjuvant carrier system (microparticle calcium phosphate + protein/mucopolysaccharide coacervate)?

Answer (claim core): US7722857 protects an immunoadjuvant system where at least two different microparticle carriers exist: carbonate-containing MCP and protein–mucopolysaccharide coacervate precipitates, used to carry immunostimulating substances for systemic, local tumor, or ex vivo cell-mixed immunotherapy.

Claim 1 is the anchor: dual microparticle carriers with strict MCP characterization + coacervation precipitate

Claim 1 requires, in combination:

1. Immunoadjuvant comprising immunostimulating substances carried by each of two or more kinds of different microparticle carriers, with at least:

2. Carrier (a): microparticle calcium phosphate meeting all of:

   • Ca/P molar ratio ≥ 1.3
   • Carbonate groups CO3^2−: 1 to 15 wt%
   • Crystallinity window by XRD (Cu Kα):
     • Not lower than crystallinity defined by broad peaks with centers at 2θ = 26°, 32°, 34°, and a shoulder with Miller index (hkl) 300 at 33°
     • Not higher than crystallinity defined by peaks/shoulders at 26°, 28.1°, 29°, 32°, 33°, 34°
     • Plus separation criteria: peaks with Miller indices 211 and 112

3. Carrier (b): coacervated precipitate of a soluble protein and a mucopolysaccharide

   • Formed by coacervation

4. A system-level requirement: the MCP carrier and the coacervate precipitate are among the “two or more kinds of different microparticle carriers” used in the immunoadjuvant.

Practical infringement lens: If a product uses calcium phosphate microparticles but with Ca/P < 1.3, carbonate outside 1–15 wt%, or an XRD crystallinity pattern outside the defined bounds, claim 1 is not met even if it uses coacervates elsewhere. Conversely, if both carrier types are present but the precipitate is not coacervated protein + mucopolysaccharide, claim 1 is not met.

Dependent claims tighten specific ingredients and use contexts

Key dependent claim limits:

• Claim 2: MCP maximum diameter ≤ 1 μm
• Claim 3: soluble protein is albumin
• Claim 4: mucopolysaccharide is heparin
• Claim 5: coacervate precipitates are crosslinked using an inter-protein molecule crosslinking agent
• Claim 6: immunostimulating substance consists of cytokines/chemokines/cell growth factors/hormones inducers
• Claim 7: immunostimulating substance consists of a broad list including tuberculin/PPD, microbial ingredients, LPS, lipid A, oligonucleotides, β-glucans, Keyhole limpet hemocyanin, muramyl dipeptide, bestatin, levamisole, cytokines/chemokines/growth factors/hormones
• Claim 8: microbial extracts are alcohol/acetone/pyridine/hot water extracts
• Claim 9: microorganisms are bacteria
• Claim 10: immunoadjuvant for internal administration with an antigen to induce systemic immune response
• Claim 11: antigen selection includes broad classes of microbial/fungal/tumor antigens
• Claim 12: immunoadjuvant for intra-tumor tissue administration using antigen denatured by a physical means to induce antitumor response
• Claim 13: physical means includes microwave, RFA, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation, laser, sonic disruption
• Claim 14–15: post-external mixing with immunocompetent cells (DCs, macrophages, B/T cells, NK/NKT, hematopoietic stem cells) for systemic response
• Claim 16: vaccine containing immunoadjuvant + antigen

What this means for patent-protection scope

• Strong “material limitation” spine: the MCP’s Ca/P, carbonate wt%, and XRD crystallinity banding are the major novelty holders because they reduce the set of covered calcium phosphate formulations dramatically.
• Weak “payload limitation”: immunostimulating substances are broadly defined; this increases coverage if the payload is carried on/in the carriers without changing carrier identity.
• Use claims are method-of-therapy scope: many subclaims are for administration context. Those can face obviousness/enablement issues depending on prior art combining adjuvant with those antigens and delivery modes.

---

When does US 7,722,857 lose exclusivity and how long is the US term?

Answer: Term length depends on filing date and maintenance status, but the patent term for a US utility patent is generally 20 years from the earliest effective non-provisional filing date, subject to adjustment/extinction and any pediatric extension. Without the patent’s filing and priority data plus PTA/PTE and maintenance history, an exact exclusivity end date cannot be stated from the information provided.

---

How strong is the patent estate for US 7,722,857: validity risks on novelty and obviousness?

Answer (issue map): The strongest validity attack routes are directed at Claim 1’s combination requirement: (1) specific carbonate-containing, Ca/P≥1.3, microparticle calcium phosphate with that XRD crystallinity specification, plus (2) coacervation-derived protein/mucopolysaccharide precipitate used as an immunostimulant carrier in the same immunoadjuvant.

Potential novelty/obviousness pressure points

1. Calcium phosphate adjuvant prior art is extensive

   • Many vaccines and immunotherapy compositions use calcium phosphate (including carbonate-containing variants) to promote antigen uptake and immune activation.
   • The differentiator in US7722857 is the tight physicochemical window (Ca/P, carbonate wt%, and XRD crystallinity constraints).

2. Protein–polysaccharide coacervates are also prior art in drug delivery

   • Coacervation of proteins with mucopolysaccharides is known in encapsulation/controlled release.
   • The key validity question is whether the prior art disclosed those coacervate precipitates specifically as immunoadjuvant microparticle carriers carrying immunostimulating substances in a configuration that also includes the defined MCP.

3. XRD “Miller index” and 2θ window is a litigation focal point

   • Claim 1 requires crystallinity “not lower than” and “not higher than” defined by peaks/shoulders and specific indices.
   • This can cut both ways:
     • It can protect against broad calcium phosphate prior art that is “close but not inside the window.”
     • It can also become an invalidity lever if earlier references show overlapping XRD patterns and carbonate/Ca/P ranges, even if the documentation is less precise than the claim language.

4. Broad payload lists may not save obviousness

   • Claim 7’s inclusion of many immunostimulants (LPS, lipid A, oligos, β-glucans, PPD, muramyl dipeptide, etc.) may be viewed as routine selection, provided the carrier system and immunostimulant loading are already taught.

Enablement and indefiniteness risk areas (practical)

• The claim uses detailed analytical criteria (XRD peaks, shoulders, Miller indices, Ca/P, carbonate wt%). Those can support definiteness, but they also invite disputes over:
  • measurement reproducibility,
  • definition of “microparticle calcium phosphate having size phagocytizable by cells” (functional language),
  • how different batches map to the “crystallinity defined by appearance of broad peaks” criteria.

---

What formulations are protected by US 7,722,857 (and what is design-around potential)?

Answer: Protected formulations must contain:

• MCP meeting the specific Ca/P, carbonate wt%, and XRD crystallinity bounds (plus ≤1 μm option in claim 2), and
• a coacervate precipitate of soluble protein + mucopolysaccharide (albumin + heparin option), optionally inter-protein crosslinking.

High-leverage design-around levers

• Carrier (a) MCP spec: adjust carbonate content below 1 wt% or above 15 wt%, lower Ca/P below 1.3, or shift crystallinity outside the defined XRD peak/shoulder pattern. Any of these can move the product outside claim 1.
• Carrier (b) coacervation: use a different protein/polysaccharide assembly method (e.g., simple adsorption, ionic complexation without coacervation, layer-by-layer) and claim 1 can fail.
• Do not use two “different microparticle carriers” of the claimed types. If only one type exists, claim 1 fails.

---

What generic entry risks exist for immunoadjuvants based on US 7,722,857?

Answer: “Generic” entry is usually irrelevant in the classic small-molecule sense because immunoadjuvant systems are complex biological/biomaterial products. The risk shifts to:

• biosimilar-like development strategies for combination biologics,
• manufacturing/IP barriers around carrier physicochemical parameters (XRD, carbonate, Ca/P),
• paragraph IV-equivalent challenges are less straightforward because immunoadjuvant-only products often are not approved under Abbreviated New Drug pathways.

The most credible entry risk is infringement exposure for any competitor that markets an adjuvant-vaccine formulation replicating the two carrier system and MCP spec.

---

How does US 7,722,857 compare with other calcium phosphate adjuvant and coacervate immunoadjuvant teachings?

Answer: US7722857 sits at the intersection of two large patent families:

• calcium phosphate microparticle adjuvants, and
• protein/polysaccharide coacervate delivery systems. The claim’s enforceability depends on the overlap: whether earlier art disclosed both architectures in one immunoadjuvant system with the MCP’s specific analytical criteria.

Competitive landscape implication

If a competitor uses calcium phosphate nanoparticles but not the carbonate/Ca/P/XRD window, it is likely outside claim 1. If it uses coacervate protein/polysaccharide precipitates but without the claimed MCP, it is likely outside claim 1. If it includes both, it must also validate crystallinity/carbonate parameters under its own manufacturing method.

---

What patent litigation affects US 7,722,857?

Answer: Litigation impact cannot be determined from the claim text alone. No litigation docket data is included in the provided inputs, so any statement about enforcement posture, validity challenges, or settlements would be unsupported.

---

What is the Orange Book status of US 7,722,857?

Answer: US patents covering immunoadjuvant formulations are not necessarily tied to an Orange Book NDA listing in a way that can be determined from the inputs. No product, NDA/BLA number, or Orange Book listing data is provided here, so status cannot be established.

---

Key Takeaways

• Claim 1 is the enforceability hinge: it requires both (a) carbonate-containing calcium phosphate microparticles with Ca/P ≥ 1.3 and a highly specific XRD crystallinity window plus (b) coacervated soluble protein + mucopolysaccharide precipitates as different microparticle carriers.
• Payload claims are broad: immunostimulating substances can be many immunostimulants, antigens, cytokines, and microbial components; carrier identity and characterization dominate infringement.
• Validity attacks likely target the “combination with precise MCP characterization”: whether prior art already disclosed that specific carbonate/Ca/P/XRD window calcium phosphate microparticle coupled to coacervate protein/polysaccharide immunostimulant carrier systems.
• Design-around is parameter-driven: altering carbonate wt%, Ca/P, or XRD crystallinity bounds for MCP, or replacing coacervation with another assembly method, is the clearest path away from claim 1.

---

FAQs

1. Which elements of US 7,722,857 most easily trigger infringement in a calcium phosphate vaccine adjuvant product?
   The MCP’s Ca/P ≥ 1.3, carbonate 1–15 wt%, and XRD crystallinity pattern plus the presence of coacervated protein/mucopolysaccharide precipitate as a different microparticle carrier.

2. Does US 7,722,857 cover immunostimulant-only carrier particles without an antigen?
   The claims are framed as an immunoadjuvant and include explicit vaccine contexts (claim 16) and administration contexts with antigens (claim 10); antigen presence is strongly embedded in the practical use subclaims.

3. Are albumin and heparin required for the broadest protection?
   No. Albumin (claim 3) and heparin (claim 4) are dependent options; claim 1 requires only a soluble protein and a mucopolysaccharide formed by coacervation.

4. If a competitor uses non-coacervate protein–polysaccharide complexes, do they infringe claim 1?
   Likely not, because claim 1 requires coacervation to form the protein/mucopolysaccharide precipitate carrier.

5. How can a developer test whether its calcium phosphate meets the claim 1 XRD criteria?
   By generating Cu Kα XRD profiles and mapping peaks/shoulders to the specified 2θ centers and Miller indices described in claim 1, then verifying carbonate content and Ca/P molar ratio.

---

References (APA)

1. United States Patent 7,722,857. (n.d.). Immunoadjuvant and vaccine containing the same.

Details for Patent 7,722,857

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Par Pharmaceutical Companies, Inc.	APLISOL	tuberculin, purified protein derivative	Injection	103782	April 20, 1998		2026-01-06
Sanofi Pasteur Limited	TUBERSOL	tuberculin, purified protein derivative	Injection	103941	February 24, 2000		2026-01-06